Drug – bio-affecting and body treating compositions – Extract – body fluid – or cellular material of undetermined... – Tissue – other than lymphoid tissue
Reexamination Certificate
2005-11-29
2005-11-29
Lankford, Jr., Leon B. (Department: 1651)
Drug, bio-affecting and body treating compositions
Extract, body fluid, or cellular material of undetermined...
Tissue, other than lymphoid tissue
C424S520000, C435S325000, C435S366000, C435S190000, C514S001000
Reexamination Certificate
active
06969532
ABSTRACT:
A new chemical compound for treating human inflammatory diseases, tissue damage, stroke, septic shock and cancer. This chemical compound is produced from a process including the following steps: (a) washing human foreskin fibroblasts with a fresh DMEM medium then incubated in a fresh medium containing 2.5%-10% fetal bovine serum for at least 8 hours to form a proliferating phase medium (PPM); (b) subjecting the proliferating phase medium to a 10-kDa ultrafiltration membrane to separate the proliferating phase medium into a <10 kDa fraction, which passes through the 10-kDa ultrafiltration membrane, and a >10 kDa fraction, which is retained by the 10-kDa ultrafiltration membrane; (c) Chromatographing the <10 kDa fraction on a Superdex 30 column by FPLC to separate the <10 kDa fraction into five post-FPLC fractions; (d) Injecting the second post-FPLC fraction into a C18column in a HPLC system with a gradient elute from 10% to 50% acetonitrile and water containing 0.1% trifluoroacetic acid, to separate the second post-FPLC fraction into five post-HPLC fractions; and (e) collecting the fourth post-FPLC fraction for further purification. Fluorescence spectroscopy shows that this product is a derivative of trypophan or trypophan-like, and mass spectrometry indicates that it has a molecular weight of about 604 daltons with a minor peak having a molecular weight of about 779 daltons.
REFERENCES:
patent: 5776967 (1998-07-01), Kreft et al.
patent: 5869524 (1999-02-01), Failli
patent: 6140515 (2000-10-01), Chen et al.
Lankford , Jr. Leon B.
Liauh M. Wayne
Liauh W. Wayne
Wu Kenneth K.
LandOfFree
Compounds inhibiting COX-2 and iNOS promoter activities does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds inhibiting COX-2 and iNOS promoter activities, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds inhibiting COX-2 and iNOS promoter activities will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3470511